Clinical Trial Update: Korean Post-marketing Surveillance for Reyataz®

View source ↗

Summary

A Korean post-marketing surveillance study assessing the safety of Reyataz (atazanavir) in individuals with HIV infection has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• REYATAZ (atazanavir)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: HIV-1 | Status: COMPLETED